Possibilities for using monoclonal antibodies in oncology;Principales utilisations thérapeutiques des anticorps monoclonaux en cancérologie

Cancer/Radiotherapie

Volumn 6, Issue SUPPL. 1, 2002, Pages

  Penault Llorca, F ^a   Etessami, A ^b   Bourhis, J ^b  

^a CENTRE JEAN PERRIN   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cytotoxic drugs; Monoclonal antibodies; Tumor cells

Indexed keywords

ABCIXIMAB; CETUXIMAB; CYTOTOXIC AGENT; DACLIZUMAB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RITUXIMAB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

BREAST CANCER; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONFERENCE PAPER; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; LYMPHOMA; ONCOLOGY; PRIORITY JOURNAL; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOMA; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 17344380984     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Baselga J, Norton L, Masui H. Antitumor effect of doxorubicine in combination with anti-EGFr monoclonal antibody. J Natl Cancer Inst. 1993;85:1327-33.
2. Baselga J, Pfister D, Cooper MR. Phase I studies of anti-EGFr chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
3. Behr TM, Behe M, Worman B. Trastuzumab and breast cancer. Letter to the editor. N Eng J Med 2001;345:996.
4. Behr TM, Griesinger F, Riggert J. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with iodine-131-chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Result of a pilot study. Cancer 2002;94:1363-72.
5. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol 2001;2:378-84.
6. Cohen RB, Falcey JW, Paulter VJ. Safety profile of the monoclonal antibody IMC-C225, an anti-EGFr. Used in the treatment of EGFr-positive tumors (abstract). Proc Am Soc Clin Oncol 2000;asbt 1862.
7. Etessami A, Bourhis J. Cetuximab. Drugs of the Future 2000;25:895-9.
8. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the EGFr in a human xenograft model. Clin Cancer Res 1995;1:1311-8.
9. Grillo-Lopez AJ, Hedrick E, Rashford M. Rituximab: Ongoing and future clinical development. Semin Oncol 2002;29:105-12.
10. Grillo-Lopez AJ, Dallaire BK, McClure A. Monoclonal antibodies: A new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol 2001;2:301-11.
11. Huang SM, Bock JM, Hahari P. EGFr blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935-40.
12. Milas L, Mason K, Hunter N. In vivo enhancement of tumor radioresponse by C225 EGFr antibody. Clin Cancer Res 2000;6:701-6.
13. Petit AM, Rak J, Hung MC. Neutralizing antibodies against EGFr and erbB2/neu tyrosine kinases down regulares vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
14. Prewett M, Rockwell P, Rose C, Goldstein NI. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFr monoclonal antibody in combination with cisplatin. Int J Oncol 1996;9:217-24.
15. Ravdin PM, Chamness GC. The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other molecular markers. Gene 1995;159:19-27.
16. Salomon DS, Brandt R, Ciardiello F. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995:183-232.
17. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
18. Slamon DJ, Cark GM, Wong SG. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-82.
19. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. New Eng J Med 2001;344:783-92.
20. Strasser F, Betticher DC, Suter TM. Trastuzumab and breast cancer. Letter to the editor. N Eng J Med 2001;345:995-6.